Allecra Therapeutics
Manufacturing · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
10 Rue Alexandre Freund, Saint-Louis, Gr...Phone Number
+33 389689876Website
www.allecra.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Allecra Therapeutics
Allecra Therapeutics is a private, clinical-stage biopharmaceutical company founded in 2013, focused on developing innovative therapies to combat antibiotic resistance. Their lead product, cefepime/enmetazobactam, has demonstrated superiority over standard treatments in patients with complicated urinary tract infections and is preparing for marketing approval in the U.S. and EU. The company aims to address the urgent need for effective antibiotics in the face of rising antimicrobial resistance, particularly against Extended-Spectrum β-lactamase-producing pathogens. Allecra Therapeutics seeks partnerships for further development and commercialization of its products.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Allecra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Allecra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Allecra Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Allecra Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Allecra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Allecra Therapeutics has new funding data
Product Launch: Get notified when Allecra Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Allecra Therapeutics
Check out if Allecra Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Allecra Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Allecra Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Allecra Therapeutics.
Allecra Therapeutics financials insights
Gather financial insights about Allecra Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$19.7M
2016
Series B
$24.7M
Allecra Therapeutics Tech Stack
A closer look at the technologies used by Allecra Therapeutics
Allecra Therapeutics News & Media
Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
SAINT-LOUIS, France & WEILL AM RHEIN, Germany--(BUSINESS WIRE)--Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today that the U.S. Food and Drug Administration (FDA) has approved EXBLIFEP® (cefepime/enmetazobactam), as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older. Allecra has also received a five-year marketing exclusivity extension fromAllecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
SAINT-LOUIS, France & WEIL AM RHEIN, Germany--(BUSINESS WIRE)--Allecra Therapeutics (“Allecra”) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cefepime/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections (cUTIs). Upon approval, the antibiotic combination will be marketed uAllecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority
SAINT-LOUIS, France & WEIL AM RHEIN, Germany--(BUSINESS WIRE)--Allecra Therapeutics (“Allecra”) announced today that the final results from its Phase 3 ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract infections (cUTIs) have been published in the Journal of the American Medical Association (JAMA). The publication represents the first full analysis of the completed Phase 3 program, which showed that cefepime/enmetazobactam met criteAllecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
SAINT-LOUIS, France & WEIL AM RHEIN, Germany & LONDON--(BUSINESS WIRE)--ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"), a specialty pharmaceutical company with a strategic focus on hospital medicines in Europe, and Allecra Therapeutics (“Allecra”) today announced that the companies have signed an exclusive license agreement under which ADVANZ PHARMA gains the rights to develop and commercialize Allecra’s antibiotic drug candidate cefepime/enmetazobactam within the European Union, the United King
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Allecra Therapeutics
Sign Up For FreeTo access detailed company insights
Allecra Therapeutics is a private, clinical-stage biopharmaceutical company founded in 2013, focused on developing innovative therapies to combat antibiotic resistance. Their lead product, cefepime/enmetazobactam, has demonstrated superiority over standard treatments in patients with complicated urinary tract infections and is preparing for marketi... Read More
